PsychonautWiki Archive

3-MeO-PCP: Difference between revisions

← Older editNewer edit →
>Unity
m Grammatics
>Sospeedyos
Added subjective effects detail, information about the PCP2 receptor, and a note about urinary tract issues compounding with use of other drugs in the same time period
Line 23: Line 23:
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".


3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter (SERT), 42 nM for the sigma-1 receptor and 2960 nM with H1 receptor <ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref> <ref name="&quot;AMCD&quot;">Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.<ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref>
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 42 nM for the sigma-1 receptor, 216 nM for the serotonin transporter (SERT), and 2960 nM with H1 receptor <ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref> <ref name="&quot;AMCD&quot;">Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.<ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref> Like its sister compound PCP and unlike ketamine, 3-MeO-PCP shows a high affinity for inhibiting the relatively unstudied PCP2 glutamate receptor.{{Citation needed}}


Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,<ref name="chemist">Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="PCP2MXE" />
Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,<ref name="chemist">Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="PCP2MXE" />
Line 35: Line 35:
   
   
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base


Line 46: Line 47:
*'''[[Effect::Bodily control enhancement]]''' or '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control loss.
*'''[[Effect::Bodily control enhancement]]''' or '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control loss.
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.  
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.  
*'''[[Effect::Appetite suppression]]''' or '''[[Effect::Appetite enhancement]]''' - The appetite suppression present with 3-MeO-PCP can be considered to be less sharp than with traditional stimulants such as [[Cocaine]] or [[MDMA]]. For some users at low doses, it is also possible to experience a contradictory appetite enhancement effect as a result of 3-MeO-PCP's ability to suppress nausea.
*'''[[Effect::Appetite suppression]]''' or '''[[Effect::Appetite enhancement]]''' - The appetite suppression present with 3-MeO-PCP can be considered to be less sharp than with substances such as [[Cocaine]] and [[Ketamine]]. Like ketamine, this is due to the disconnection of electrical signals at high doses.  Unlike ketamine, it is also possible to experience a noticeable appetite enhancement that is less prominent than its sister compound [[PCP]].
*'''[[Effect::Nausea suppression]]'''
*'''[[Effect::Nausea suppression]]'''
*'''[[Effect::Restless legs]]'''
*'''[[Effect::Restless legs]]'''
Line 153: Line 154:


===Urinary tract effects===
===Urinary tract effects===
In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:
In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Increased urinary tract effects will compound with usage of other drugs like amphetamine even if the drugs are not simultaneously used.{{Citation needed}}  Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:


*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.
*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.
Line 166: Line 167:
===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Dissos}}
{{DangerousInteractions/Dissos}}
*[[MDMA]]: 3-MeO-PCP acts as a mild serotonin releasing agent and could interact negatively with the serotonin release of MDMA


==Legal status==
==Legal status==
Retrieved from "http://psy.st/wiki/3-MeO-PCP"